In 2012, Damon Runyon scientists continued unraveling the causes of cancer and discovering new ways to prevent and cure it in all of its forms.

Damon Runyon Scientists

- Demonstrated that two new immunotherapies reduce tumors in certain types of melanoma, lung, renal and other cancers.
- Led a breakthrough clinical trial of the drug vismodegib, which stopped tumor growth in a form of basal-cell carcinoma.
- Completed the first comprehensive genome sequencing of melanoma, colorectal and prostate cancers.
- Developed a noninvasive imaging technique that can distinguish between brain tumor types with 100% accuracy.
- Confirmed the existence of cancer stem cells, a major step toward understanding how to prevent recurrence.

Awards and Honors

Former Innovator Sarkis K. Mazmanian, PhD, received a “genius grant” from the MacArthur Foundation.

Former Fellows Rachel D. Green, PhD, Gregory J. Hannon, PhD, and Eckard A.F. Wimmer, PhD, were elected to the National Academy of Sciences (the science “Hall of Fame”), bringing Damon Runyon’s total to 62.

Elaine V. Fuchs, PhD, former Fellow and current Board Member, received the prestigious March of Dimes Prize, given to leaders in developmental biology.

Scott A. Armstrong, MD, PhD, former Clinical Investigator, was awarded the Paul Marks Prize for Cancer Research for his work on cancer stem cells and genomics.

Former Fellows Valerie Horsley, PhD, and Georgios Skiniotis, PhD, received the Presidential Early Career Award for Scientists and Engineers.

Damon Runyon Cancer Research Foundation
Our Mission

To accelerate breakthroughs, the Damon Runyon Cancer Research Foundation provides today’s best young scientists with funding to pursue innovative cancer research.

Research Programs

- 131 young scientists are currently being funded at 54 leading institutions in 19 states.
- $11.7 million was paid in new awards in 2012.
- The Damon Runyon-Sohn Pediatric Cancer Fellowship was launched to address the shortage of scientists focused on childhood cancers.

Financial Information

Revenue ............................................. $15.5 million
- Contributions .................................. $9.8 million
- Bequests & Trusts ............................... $0.6 million
- Drawn from Investment ....................... $4.0 million
- Other ............................................ $1.1 million

Expenses .......................................... $15.5 million
- Program ....................................... 85.8%
- Administrative ................................. 14.2%

100% of donations fund cancer research.

Our low administrative costs are paid from Damon Runyon Broadway Tickets and our endowment.

DISCOVERING THE TALENT
TO DISCOVER THE CURE

www.damonrunyon.org
1.877.7CANCER